Medincell: Half-year Liquidity Contract Statement

MONTPELLIER, France--( BUSINESS WIRE)--Regulatory News:

Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at December 31, 2025:

Over the period from 01/07/2025 to 31/12/2025, a total of:

Number of executions

Number of shares

Traded volume in EUR

Buy side

13,642

1,007,509

25,098,637.27

Sell side

14,870

1,011,529

25,113,263.98

It should be noted that Medincell increased the funds allocated to the liquidity contract by €600,000 on 11 April 2025.

The following resources were included in the liquidity account at June 30, 2025:

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.

These treatments combine active pharmaceutical ingredients with our proprietary BEPO ® / BEPO ® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable deposit.

Risperidone LAI was the first treatment based on BEPO ® technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY ®. Medincell’s risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.

A New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell’s partner, Teva.

Medincell’s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.

Headquartered in Montpellier, France, Medincell employs over 140 people representing more than 25 nationalities.

medincell.com

UZEDY ® and SteadyTeq™ are trademarks of Teva Pharmaceuticals.

This press release may contain forward-looking statements, particularly concerning the progress of the Company's clinical trials. Although the Company considers that its forecasts are based on reasonable assumptions, any statements other than statements of historical fact that may be contained in this press release relating to future events are subject to change without notice, to factors beyond the Company's control and to the Company's financial capabilities.

These statements may include, but are not limited to, any statements beginning with, followed by or including words or expressions such as "objective", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "should", "could" and other words or expressions of similar meaning or used in the negative. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control which may cause actual results, performance or achievements of the Company to differ materially from those anticipated or implied by such statements.

A list and description of such risks, hazards and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (AMF) pursuant to its regulatory obligations, including in the Company's document de base, registered with the AMF on September 4, 2018 under number I. 18-062, as well as in documents and reports to be published subsequently by the Company. Furthermore, these forward-looking statements only apply as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to publicly update these forward-looking statements, nor to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements, even if new information becomes available. The Company's updating of one or more forward-looking statements does not imply that it will or will not update these or any other forward-looking statements.

This press release is published for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of the Company in any jurisdiction whatsoever, particularly in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not intended to address the investment objectives, financial situation or specific needs of any particular recipient. It should not be relied upon as a substitute for the exercise of your own judgement. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be restricted by law in certain jurisdictions. Persons into whose possession this press release comes are required to inform themselves about and to observe any such restrictions.

APPENDICES - Rothschild Martin Maurel from 01/07/2025 to 31/12/2025

CLIENT

DATE

NB_ACHAT

NB_VENTE

QTE_ACHAT

QTE_VENTE

CAPITAUX_ACHETES

CAPITAUX_VENDUS

MEDINCELL

01/07/2025

107

10 894

4 774

179 315,24

78 675,52

MEDINCELL

02/07/2025

144

132

11 704

10 824

192 881,92

178 920,72

MEDINCELL

03/07/2025

102

7 044

115 028,52

115 098,96

MEDINCELL

04/07/2025

168

4 131

16 131

68 326,74

269 387,70

MEDINCELL

07/07/2025

100

9 333

1 833

154 927,80

30 592,77

MEDINCELL

08/07/2025

112

116

16 000

253 120,00

253 280,00

MEDINCELL

09/07/2025

110

118

9 995

10 392

159 020,45

165 336,72

MEDINCELL

10/07/2025

4 704

6 807

74 934,72

108 843,93

MEDINCELL

11/07/2025

6 941

6 441

112 235,97

104 215,38

MEDINCELL

14/07/2025

6 361

9 361

102 475,71

150 992,93

MEDINCELL

15/07/2025

7 500

121 800,00

121 875,00

MEDINCELL

16/07/2025

5 422

2 922

87 511,08

47 394,84

MEDINCELL

17/07/2025

6 228

99 461,16

99 585,72

MEDINCELL

18/07/2025

5 558

88 761,26

MEDINCELL

21/07/2025

4 787

2 787

76 400,52

44 452,65

MEDINCELL

22/07/2025

7 607

4 607

119 277,76

72 099,55

MEDINCELL

23/07/2025

113

2 668

10 168

42 821,40

162 891,36

MEDINCELL

24/07/2025

3 161

5 661

51 966,84

93 293,28

MEDINCELL

25/07/2025

118

137

10 694

183 509,04

183 402,10

MEDINCELL

28/07/2025

8 978

8 002

154 601,16

138 034,50

MEDINCELL

29/07/2025

8 664

4 514

150 320,40

77 866,50

MEDINCELL

30/07/2025

4 821

8 947

83 596,14

156 125,15

MEDINCELL

31/07/2025

9 638

4 238

164 713,42

73 020,74

SOUS TOTAL MEDINCELL

07/2025

1 816

1 935

172 833

171 433

2 837 007,25

2 814 147,28

MEDINCELL

01/08/2025

6 161

861

101 902,94

14 008,47

MEDINCELL

04/08/2025

7 125

6 375

112 218,75

101 681,25

MEDINCELL

05/08/2025

1 832

2 282

28 835,68

35 987,14

MEDINCELL

06/08/2025

5 273

6 298

82 944,29

99 193,50

MEDINCELL

07/08/2025

4 282

7 552

67 869,70

119 925,76

MEDINCELL

08/08/2025

3 149

6 354

50 415,49

101 981,70

MEDINCELL

11/08/2025

7 865

3 365

124 738,90

53 705,40

MEDINCELL

12/08/2025

3 148

4 177

49 643,96

65 996,60

MEDINCELL

13/08/2025

118

5 022

8 449

80 803,98

136 113,39

MEDINCELL

14/08/2025

5 568

8 612

90 702,72

140 461,72

MEDINCELL

15/08/2025

705

2 205

12 020,25

37 088,10

MEDINCELL

18/08/2025

103

8 664

151 100,16

151 273,44

MEDINCELL

19/08/2025

5 000

87 150,00

87 750,00

MEDINCELL

20/08/2025

7 474

132 289,80

132 588,76

MEDINCELL

21/08/2025

119

9 997

178 146,54

178 646,39

MEDINCELL

22/08/2025

102

10 391

4 391

188 908,38

79 784,47

MEDINCELL

25/08/2025

180

130

10 929

6 929

190 383,18

120 703,18

MEDINCELL

26/08/2025

100

4 183

5 683

71 236,49

97 690,77

MEDINCELL

27/08/2025

8 980

155 174,40

155 354,00

MEDINCELL

28/08/2025

4 847

5 347

83 562,28

92 289,22

MEDINCELL

29/08/2025

102

6 782

116 786,04

116 921,68

SOUS TOTAL MEDINCELL

08/2025

1 656

1 500

127 377

125 777

2 156 833,93

2 119 144,94

MEDINCELL

01/09/2025

7 686

131 891,76

132 122,34

MEDINCELL

02/09/2025

6 312

5 512

107 240,88

93 759,12

MEDINCELL

03/09/2025

5 073

7 173

85 885,89

121 869,27

MEDINCELL

04/09/2025

5 690

3 290

96 331,70

55 699,70

MEDINCELL

05/09/2025

3 985

8 085

67 187,10

136 798,20

MEDINCELL

08/09/2025

109

6 356

11 356

110 912,20

198 389,32

MEDINCELL

09/09/2025

105

8 709

161 029,41

161 639,04

MEDINCELL

10/09/2025

7 958

148 973,76

MEDINCELL

11/09/2025

108

9 000

175 500,00

175 590,00

MEDINCELL

12/09/2025

6 789

5 039

138 427,71

102 795,60

MEDINCELL

15/09/2025

3 585

72 883,05

72 847,20

MEDINCELL

16/09/2025

116

9 193

5 943

185 330,88

120 226,89

MEDINCELL

17/09/2025

149

154

14 808

18 308

300 158,16

372 018,56

MEDINCELL

18/09/2025

7 429

8 929

155 414,68

186 705,39

MEDINCELL

19/09/2025

101

7 913

5 913

168 784,29

126 242,55

MEDINCELL

22/09/2025

167

137

11 500

13 500

244 605,00

288 765,00

MEDINCELL

23/09/2025

111

106

8 500

184 620,00

185 640,00

MEDINCELL

24/09/2025

100

137

12 000

269 160,00

269 400,00

MEDINCELL

25/09/2025

6 000

133 320,00

133 980,00

MEDINCELL

26/09/2025

128

132

11 230

246 610,80

247 509,20

MEDINCELL

29/09/2025

8 150

186 961,00

187 531,50

MEDINCELL

30/09/2025

5 168

122 326,56

122 533,28

SOUS TOTAL MEDINCELL

09/2025

1 958

1 907

173 034

181 034

3 493 554,83

3 641 035,92

MEDINCELL

01/10/2025

4 467

108 950,13

109 352,16

MEDINCELL

02/10/2025

113

112

10 000

7 000

257 600,00

179 620,00

MEDINCELL

03/10/2025

785

3 785

20 912,40

99 431,95

MEDINCELL

06/10/2025

110

7 115

188 903,25

189 828,20

MEDINCELL

07/10/2025

6 692

180 884,76

181 553,96

MEDINCELL

08/10/2025

133

178

20 000

17 500

564 200,00

493 325,00

MEDINCELL

09/10/2025

139

6 101

8 601

170 583,96

242 032,14

MEDINCELL

10/10/2025

354

392

22 500

22 250

636 300,00

629 452,50

MEDINCELL

13/10/2025

9 615

9 865

296 718,90

305 815,00

MEDINCELL

14/10/2025

8 750

292 775,00

293 912,50

MEDINCELL

15/10/2025

172

190

15 750

11 750

525 892,50

392 920,00

MEDINCELL

16/10/2025

275

242

10 194

14 194

339 256,32

474 363,48

MEDINCELL

17/10/2025

121

213

20 000

672 800,00

673 600,00

MEDINCELL

20/10/2025

187

194

15 250

12 250

538 325,00

431 812,50

MEDINCELL

21/10/2025

177

254

19 000

22 000

668 420,00

775 940,00

MEDINCELL

22/10/2025

138

15 000

7 500

521 100,00

262 875,00

MEDINCELL

23/10/2025

158

267

10 853

18 353

371 715,25

631 526,73

MEDINCELL

24/10/2025

172

150

19 250

672 210,00

673 365,00

MEDINCELL

27/10/2025

154

144

5 241

188 885,64

189 724,20

MEDINCELL

28/10/2025

3 404

123 326,92

124 416,20

MEDINCELL

29/10/2025

141

128

17 283

7 399

633 594,78

271 617,29

MEDINCELL

30/10/2025

130

4 500

13 634

164 970,00

500 367,80

MEDINCELL

31/10/2025

135

3 048

3 798

117 927,12

146 109,06

SOUS TOTAL MEDINCELL

10/2025

3 013

3 502

254 798

8 256 251,93

8 272 960,67

MEDINCELL

03/11/2025

154

103

4 761

3 261

180 061,02

123 852,78

MEDINCELL

04/11/2025

223

199

12 302

13 802

445 086,36

501 702,70

MEDINCELL

05/11/2025

225

280

27 500

982 575,00

983 400,00

MEDINCELL

06/11/2025

277

224

16 000

8 500

535 200,00

280 840,00

MEDINCELL

07/11/2025

178

164

13 500

422 415,00

423 765,00

MEDINCELL

10/11/2025

266

213

10 226

6 976

312 711,08

212 628,48

MEDINCELL

11/11/2025

331

448

18 000

18 750

541 620,00

567 375,00

MEDINCELL

12/11/2025

146

300

11 000

340 670,00

341 110,00

MEDINCELL

13/11/2025

166

5 271

164 191,65

165 509,40

MEDINCELL

14/11/2025

119

117

6 983

212 422,86

212 492,69

MEDINCELL

17/11/2025

114

154

3 813

115 305,12

115 800,81

MEDINCELL

18/11/2025

3 107

93 613,91

94 142,10

MEDINCELL

19/11/2025

118

132

3 369

100 968,93

MEDINCELL

20/11/2025

231

129

6 808

2 208

198 793,60

64 959,36

MEDINCELL

21/11/2025

129

156

3 369

7 119

93 691,89

200 328,66

MEDINCELL

24/11/2025

165

193

4 494

5 344

126 461,16

150 914,56

MEDINCELL

25/11/2025

172

207

4 247

5 247

121 634,08

151 061,13

MEDINCELL

26/11/2025

128

162

5 652

164 077,56

164 247,12

MEDINCELL

27/11/2025

132

6 484

5 484

183 691,72

154 539,12

MEDINCELL

28/11/2025

208

287

20 500

575 845,00

576 255,00

SOUS TOTAL MEDINCELL

11/2025

3 500

3 813

187 386

177 386

5 911 035,94

5 585 892,84

MEDINCELL

01/12/2025

118

3 932

109 820,76

110 331,92

MEDINCELL

02/12/2025

189

13 000

8 000

347 230,00

212 080,00

MEDINCELL

03/12/2025

123

225

2 953

5 453

78 195,44

144 886,21

MEDINCELL

04/12/2025

3 319

85 928,91

86 028,48

MEDINCELL

05/12/2025

5 010

4 010

130 610,70

104 540,70

MEDINCELL

08/12/2025

139

310

12 066

15 566

321 196,92

415 456,54

MEDINCELL

09/12/2025

138

3 997

11 997

106 879,78

326 798,28

MEDINCELL

10/12/2025

122

227

6 460

8 460

171 513,00

225 120,60

MEDINCELL

11/12/2025

2 760

76 396,80

77 611,20

MEDINCELL

12/12/2025

118

174

6 171

3 671

173 713,65

103 632,33

MEDINCELL

15/12/2025

134

5 356

2 856

145 308,28

77 968,80

MEDINCELL

16/12/2025

103

227

5 738

6 238

152 343,90

166 367,46

MEDINCELL

17/12/2025

108

7 678

3 358

201 931,40

87 946,02

MEDINCELL

18/12/2025

3 117

3 187

80 200,41

82 224,60

MEDINCELL

19/12/2025

2 598

2 168

65 989,20

55 218,96

MEDINCELL

22/12/2025

1 931

47 830,87

47 888,80

MEDINCELL

23/12/2025

2 952

3 952

73 386,72

99 037,12

MEDINCELL

24/12/2025

117

1 867

2 894,58

46 600,32

MEDINCELL

29/12/2025

745

18 513,25

18 602,65

MEDINCELL

30/12/2025

1 916

2 666

47 555,12

66 623,34

MEDINCELL

31/12/2025

265

4 965

6 513,70

125 118,00

SOUS TOTAL MEDINCELL

12/2025

1 699

2 213

92 081

101 101

2 443 953,39

2 680 082,33

TOTAL GENERAL MEDINCELL

S2/2025

13 642

14 870

1 007 509

1 011 529

25 098 637,27

25 113 263,98